A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications

Author:

Williams Abimbola O1ORCID,Rojanasarot Sirikan1ORCID,McGovern Alysha M1ORCID,Kumar Arun2ORCID

Affiliation:

1. Health Economics & Market Access, Boston Scientific, Marlborough, MA 01752, USA

2. Department of Pharmacy Practice & Administrative Sciences, University of Cincinnati, James L Winkle College of Pharmacy, Cincinnati, OH 45229, USA

Abstract

Aim: This review summarizes the discounting approaches recommended in current economic evaluation (EE) guidelines for healthcare programs and interventions. Materials & methods: A systematic review of EE guidelines for healthcare, published up to July 2022, was conducted. Results: A total of 52 EE guidelines were reviewed. The majority of these guidelines recommend equal discounting (80.8%) rather than differential discounting (9.6%). The rationale for equal discounting includes recommendations by the government, consistency with other countries, and economic development. However, the rationale for differential discounting is based on the interest in short-term government bonds and anticipated budget changes. Discussion: This review demonstrates variation in both discounting approaches and rates across EE guidelines and underscores the need for a global consensus on discounting approaches.

Publisher

Becaris Publishing Limited

Subject

Health Policy

Reference77 articles.

1. What is the impact of disease prevalence upon health technology assessment?;Rotily M;Best Pract. Res. Clin. Gastroenterol.,2013

2. Guidelines for the clinical and economic evaluation of health care technologies;Guyatt G;Soc. Sci. Med.,1986

3. The cost–effectiveness of what in health and care?;Mitchell PM;Defining the Value of Medical Interventions: Normative and Empirical Challenges.,2021

4. New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds.;Pagliarulo N;Biopharma Dive,2021

5. US Food and Drug Administration (FDA). Approved cellular and gene therapy products. (2022). www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3